Unknown

Dataset Information

Fulminant myocarditis following coronavirus disease 2019 vaccination: a case report.


ABSTRACT:

Background

The BNT162b2 vaccine received emergency use authorization from the U.S. Food and Drug Administration for the prevention of severe coronavirus disease 2019 (COVID-19) infection. We report a case of biopsy and magnetic resonance imaging (MRI)-proven severe myocarditis that developed in a previously healthy individual within days of receiving the first dose of the BNT162b2 COVID-19 vaccine.

Case summary

An 80-year-old female with no significant cardiac history presented with cardiogenic shock and biopsy-proven fulminant myocarditis within 12 days of receiving the BNT162b2 COVID-19 vaccine. She required temporary mechanical circulatory support, inotropic agents, and high-dose steroids for stabilization and management. Ultimately, her cardiac function recovered, and sh

SUBMITTER: Agdamag ACC 

PROVIDER: S-EPMC8790078 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature